ClinicalTrials.gg
CompletedNCT01179581Updated Mar 24, 2011

First-in-Human Single Ascending and Multiple Dose of GLPG0634

A Phase 1 interventional study of GLPG0634 and placebo in Healthy, sponsored by Galapagos NV. Completed at 1 site in Belgium. Open to male participants aged 40 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-03-24.

Sponsored by Galapagos NV · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
40 Years to 60 Years
Sex
Male
01

Study summary

The purpose of the study is to evaluate the safety and tolerability of single ascending (SAD) and multiple (MD) oral doses of GLPG0634 compared to placebo (with and without food).

Also, pharmacokinetics (PK) and pharmacodynamics (PD) of GLPG0634 after single and multiple oral administration will be evaluated, and, if applicable, the maximum tolerated dose determined.

02

Conditions studied

  • Healthy

Keywords

  • Safety
  • Tolerability
  • Pharmacokinetics
03

In context

Lead sponsor

Galapagos NV is the lead sponsor of 103 studies on the registry; none are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 11 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 60 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • healthy male, age 40-60 years
  • (BMI) between 18-30 kg/m², inclusive.

Exclusion criteria

Exclusion Criteria:

  • any condition that might interfere with the procedures or tests in the study
  • smoking
  • drug or alcohol abuse
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    1

    single ascending doses

    Drug: GLPG0634

  • Placebo comparator
    2

    single dose placebo

    Drug: placebo

  • Experimental
    3

    multiple dose, 10 days, capsules (dosing depends on outcome of single-dose part; can be once or twice daily).

    Drug: GLPG0634

  • Placebo comparator
    4

    multiple dose, capsules, 10 days; scheme to match that of Study Arm 3.

    Drug: placebo

Interventions

  • single ascending doses, oral solution (1 to 10 mg/dose) and capsules (10 to 200 mg/dose)

  • Drugplacebo

    single dose, oral solution or capsule (matching corresponding study medication)

  • multiple dose, capsule, 10 days

  • Drugplacebo

    multiple dose, capsule, 10 days

06

What researchers measure

Primary outcomes

  1. Safety and tolerability of single and multiple dosing

    Tests will be performed to assess whether the study drug has any potentially adverse effect (laboratory tests on blood and urine for functioning of organs; cardiovascular testing, i.e. of heart and bloodcirculation). Also, participants will carefully be monitored by medical staff for vital signs, and asked to report any side effect experienced in the course of the study.

    Time frame: up to 10 days postdose

Secondary outcomes

  1. Pharmacokinetics of single and repeated doses, including effect of food.

    Bloodsamples are taken on various timepoints to assess how much of the study drug is taken up in the blood (absorption), how long it stays in the blood (excretion), and whether any "breakdown"-products of the drug are present (metabolism).

    Time frame: up to 10 days postdose

07

Study locations

1 site
  • SGS Stuivenberg
    Antwerp, Belgium
08

References and documents

Publications

  • Namour F, Diderichsen PM, Cox E, Vayssiere B, Van der Aa A, Tasset C, Van't Klooster G. Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection. Clin Pharmacokinet. 2015 Aug;54(8):859-74. doi: 10.1007/s40262-015-0240-z. PubMed 25681059 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2010, a primary completion of Mar 2011 and a completion of Mar 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 10, 2010
First posted
Aug 11, 2010
Start
Aug 2010
Primary completionActual
Mar 2011
CompletionActual
Mar 2011
Last update
Mar 24, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 24, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01179581
Lead sponsor
Galapagos NV
First posted
Aug 11, 2010
Start date
Aug 2010
Primary completion
Mar 2011
Completion
Mar 2011
Last update
Mar 24, 2011

Study contacts

Gerben van 't Klooster, PhD
study director · Galapagos NV
Eva Vets, MD
principal investigator · SGS Stuivenberg

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GLPG0634

Start the discussion